Using patient-derived melanoma samples, we found that a large majority of progressed samples (63%), from patients treated with BRAFi or BRAFi + MEK inhibitor (MEKi), showed reduced HAT1 expression levels compared with matched pre-treatment melanoma samples, indicating that HAT1 is clinically relevant. Here, MAP2K7 is linked to melanoma.